Literature DB >> 3508245

Modulation of ischemic-induced damage to cerebral adenylate cyclase in gerbils by calcium channel blockers.

B C Christie-Pope1, G C Palmer.   

Abstract

It has been previously established that prolonged bilateral carotid occlusion followed by recirculation produces damage to the synaptic enzyme adenylate cyclase in the frontal cortex of the gerbil. Since calcium entrance into the brain may account in part for the deleterious consequences of stroke, the present study examined whether pretreatment with calcium channel blockers would modify the effects of 60 min of bilateral ischemia plus 40 min of reflow on various parameters of cortical adenylate cyclase activation. In this context activation of cerebral homogenates by norepinephrine with or without 5'-guanylyl imidodiphosphate was preserved by pretreatment of ischemic gerbils with verapamil but worsened by flunarizine. In contrast, in particulate fractions (treated with EGTA to reduce metallic ion levels) the damage to the Mn2+-sensitive catalytic site of adenylate cyclase was prevented only by flunarizine. Pretreatment with the two calcium channel blockers resulted in an elevated basal activity of the enzyme, thereby reducing the response in the homogenate preparation to forskolin. Gerbils pretreated with verapamil tended to have an increased ability for survival resulting from the ischemic episode. Under in vitro conditions the enzyme preparations were not markedly influenced by either drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3508245     DOI: 10.1007/bf00999355

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  30 in total

1.  Magnesium regulation of the beta-receptor-adenylate cyclase complex. I. Effects of manganese on receptor binding and cyclase activation.

Authors:  S Y Cech; M E Maguire
Journal:  Mol Pharmacol       Date:  1982-09       Impact factor: 4.436

2.  Relationship between calcium accumulation and recovery of cat brain after prolonged cerebral ischemia.

Authors:  K A Hossmann; W Paschen; L Csiba
Journal:  J Cereb Blood Flow Metab       Date:  1983-09       Impact factor: 6.200

3.  Metabolic profile of hippocampal regions after bilateral ischemia and recovery.

Authors:  M S Abel; D W McCandless
Journal:  Neurochem Res       Date:  1982-07       Impact factor: 3.996

Review 4.  Calcium antagonists, cerebral ischemia and vasospasm.

Authors:  B Weir
Journal:  Can J Neurol Sci       Date:  1984-05       Impact factor: 2.104

5.  Protection with flunarizine against hypoxic-ischaemic damage of the rat cerebral cortex. A quantitative morphologic assessment.

Authors:  J Van Reempts; M Borgers; L Van Dael; J Van Eyndhoven; M Van De Ven
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-03

6.  Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog.

Authors:  P A Steen; L A Newberg; J H Milde; J D Michenfelder
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

Review 7.  Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

8.  A gerbil model of cerebral ischemia suitable for drug evaluation.

Authors:  D M Jarrott; F R Domer
Journal:  Stroke       Date:  1980 Mar-Apr       Impact factor: 7.914

9.  Brain injury, edema, and vascular permeability changes induced by oxygen-derived free radicals.

Authors:  P H Chan; J W Schmidley; R A Fishman; S M Longar
Journal:  Neurology       Date:  1984-03       Impact factor: 9.910

Review 10.  Forskolin: a unique diterpene activator of cyclic AMP-generating systems.

Authors:  K B Seamon; J W Daly
Journal:  J Cyclic Nucleotide Res       Date:  1981
View more
  1 in total

1.  Free radicals generated by xanthine oxidase-hypoxanthine damage adenylate cyclase and ATPase in gerbil cerebral cortex.

Authors:  G C Palmer
Journal:  Metab Brain Dis       Date:  1987-12       Impact factor: 3.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.